$PHIO
Phio Pharmaceuticals Corp.

2012 Q4 Form 10-Q Financial Statement

#000119312512467372 Filed on November 13, 2012

View on sec.gov

Income Statement

Concept 2012 Q4 2012 Q3 2011 Q3
Revenue $40.00K $57.00K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $620.0K $540.0K $1.040M
YoY Change -34.04% -48.08%
% of Gross Profit
Research & Development $1.140M $1.214M $1.126M
YoY Change -26.45% 7.82%
% of Gross Profit
Depreciation & Amortization $30.00K $40.00K $40.00K
YoY Change -25.0% 0.0%
% of Gross Profit
Operating Expenses $1.750M $1.753M $1.126M
YoY Change -29.72% 55.68%
Operating Profit -$1.696M -$2.167M
YoY Change -21.74%
Interest Expense $0.00 $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $0.00 $53.00K $123.0K
YoY Change -100.0% -56.91%
Pretax Income -$1.710M -$1.640M -$2.040M
YoY Change -30.2% -19.61%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.710M -$1.644M -$2.043M
YoY Change -30.2% -19.53%
Net Earnings / Revenue -4275.0% -2884.21%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.334B -$3.067B -$8.033B
COMMON SHARES
Basic Shares Outstanding 158.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2012 Q4 2012 Q3 2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.130M $6.280M
YoY Change 926.0%
Cash & Equivalents $5.127M $6.278M
Short-Term Investments
Other Short-Term Assets $260.0K $190.0K
YoY Change 8.33%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $5.392M $6.475M
YoY Change 302.69%
LONG-TERM ASSETS
Property, Plant & Equipment $198.0K $235.0K
YoY Change -44.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change
Total Long-Term Assets $200.0K $237.0K
YoY Change -43.66%
TOTAL ASSETS
Total Short-Term Assets $5.392M $6.475M
Total Long-Term Assets $200.0K $237.0K
Total Assets $5.592M $6.712M
YoY Change 230.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $416.0K $155.0K
YoY Change 7.49%
Accrued Expenses $767.0K $877.0K
YoY Change 40.99%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $10.00K $10.00K
YoY Change -66.67%
Total Short-Term Liabilities $1.679M $1.411M
YoY Change -5.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $30.00K
YoY Change
Total Long-Term Liabilities $30.00K $0.00
YoY Change -94.12%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.679M $1.411M
Total Long-Term Liabilities $30.00K $0.00
Total Liabilities $1.706M $1.411M
YoY Change -25.21%
SHAREHOLDERS EQUITY
Retained Earnings $17.16M $15.45M
YoY Change
Common Stock $16.00K $16.00K
YoY Change 60.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.840M -$4.274M
YoY Change
Total Liabilities & Shareholders Equity $5.592M $6.712M
YoY Change 230.11%

Cashflow Statement

Concept 2012 Q4 2012 Q3 2011 Q3
OPERATING ACTIVITIES
Net Income -$1.710M -$1.644M -$2.043M
YoY Change -30.2% -19.53%
Depreciation, Depletion And Amortization $30.00K $40.00K $40.00K
YoY Change -25.0% 0.0%
Cash From Operating Activities -$1.150M -$1.250M -$2.120M
YoY Change -59.07% -41.04%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $0.00 $0.00
YoY Change 0.0%
Acquisitions
YoY Change
Other Investing Activities $10.00K $20.00K $0.00
YoY Change -120.0%
Cash From Investing Activities $10.00K $20.00K $0.00
YoY Change -116.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -10.00K 2.540M
YoY Change -100.0% -100.39%
NET CHANGE
Cash From Operating Activities -1.150M -1.250M -2.120M
Cash From Investing Activities 10.00K 20.00K 0.000
Cash From Financing Activities 0.000 -10.00K 2.540M
Net Change In Cash -1.140M -1.240M 420.0K
YoY Change -1525.0% -395.24%
FREE CASH FLOW
Cash From Operating Activities -$1.150M -$1.250M -$2.120M
Capital Expenditures -$10.00K $0.00 $0.00
Free Cash Flow -$1.140M -$1.250M -$2.120M
YoY Change -59.29% -41.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
158670223 shares
CY2011Q3 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
1000
CY2011Q3 rxii Value Of Shares Agreed To Purchase Under Agreement
ValueOfSharesAgreedToPurchaseUnderAgreement
9500000
CY2011Q3 rxii Amount Of Investment
AmountOfInvestment
9500000
CY2011Q3 rxii Onetime Milestone Payment To Be Paid Under Agreement
OnetimeMilestonePaymentToBePaidUnderAgreement
350000
CY2011Q3 rxii Maximum Percentage Of Shares Owned By Stockholders
MaximumPercentageOfSharesOwnedByStockholders
0.09999 pure
CY2011Q3 rxii Percentage Of Fully Diluted Shares Converted
PercentageOfFullyDilutedSharesConverted
0.83 pure
CY2011Q3 rxii Number Of Shares Agreed To Purchase Under Agreement
NumberOfSharesAgreedToPurchaseUnderAgreement
9500 shares
CY2012Q3 rxii Closing Price Of Common Stock
ClosingPriceOfCommonStock
0.106
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
988559
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.12
CY2012Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1500000000 shares
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
90000000 shares
CY2012Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2012Q3 us-gaap Other Assets
OtherAssets
2000
rxii Fair Value Of Common Stock Issued In Exchange For Services Or Claims
FairValueOfCommonStockIssuedInExchangeForServicesOrClaims
304000
CY2012Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
144000
CY2012Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
53000
CY2012Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
370000
CY2012Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
53000
CY2012Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
15445000
CY2012Q3 us-gaap Assets
Assets
6712000
CY2012Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
53000
CY2012Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1411000
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6278000
CY2012Q3 us-gaap Grants Receivable
GrantsReceivable
800000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.10
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
63847938 shares
CY2012Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6712000
CY2012Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
157500191 shares
CY2012Q3 us-gaap Common Stock Value
CommonStockValue
16000
CY2012Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
9575 shares
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1895232 shares
CY2012Q3 us-gaap Liabilities
Liabilities
1411000
CY2012Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2012Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
9000
CY2012Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
877000
CY2012Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
9575 shares
CY2012Q3 us-gaap Preferred Stock Value
PreferredStockValue
9575000
CY2012Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
235000
CY2012Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100439841 shares
CY2012Q3 us-gaap Assets Current
AssetsCurrent
6475000
CY2012Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11155000
CY2012Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q3 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
9575000
CY2012Q3 us-gaap Stockholders Equity
StockholdersEquity
-4274000
CY2012Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
14275
CY2012Q3 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
15445000
CY2012Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
155000
CY2003Q4 us-gaap Stockholders Equity
StockholdersEquity
-89000
CY2004Q4 us-gaap Stockholders Equity
StockholdersEquity
-968000
CY2005Q4 us-gaap Stockholders Equity
StockholdersEquity
-450000
CY2006Q4 us-gaap Stockholders Equity
StockholdersEquity
-268000
CY2007Q4 us-gaap Stockholders Equity
StockholdersEquity
10823000
CY2008Q4 us-gaap Stockholders Equity
StockholdersEquity
8968000
CY2009Q4 us-gaap Stockholders Equity
StockholdersEquity
741000
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
2430000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2003 us-gaap Net Income Loss
NetIncomeLoss
-89000
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1500000000 shares
CY2011Q4 us-gaap Due From Affiliate Current
DueFromAffiliateCurrent
597000
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1776000
CY2011Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
186000
CY2011Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
53000
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
816000
CY2011Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
53000
CY2011Q4 us-gaap Assets
Assets
1694000
CY2011Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
53000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
503000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2011Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
500000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
shares
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1694000
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
157500191 shares
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2011Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2011Q4 us-gaap Liabilities
Liabilities
2281000
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2011Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
29000
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
544000
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
355000
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100439841 shares
CY2011Q4 us-gaap Assets Current
AssetsCurrent
1339000
CY2011Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3680000
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
-587000
CY2011Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
5000
CY2011Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
4277000
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
387000
CY2011Q4 rxii Number Of Shares Authorized At Incorporation
NumberOfSharesAuthorizedAtIncorporation
1000 shares
CY2011Q3 rxii Maximum Amount Of Funding
MaximumAmountOfFunding
1500000
CY2012Q2 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
9500 shares
CY2012Q2 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
1026736
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2513000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5074000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33697704 shares
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
3527000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10280000
us-gaap Net Income Loss
NetIncomeLoss
-7766000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5206000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7766000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4652000
rxii Interest Income Expense
InterestIncomeExpense
-1000
rxii Research And Development Employee Stock Based Compensation Expense
ResearchAndDevelopmentEmployeeStockBasedCompensationExpense
471000
rxii Research And Development Non Employee Stock Based Compensation Expense
ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense
-49000
rxii Common Stock Warrants Issued For General And Administrative Expenses
CommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses
91000
rxii Combined Results Of Operation Of Cumulative Period Since Inception
CombinedResultsOfOperationOfCumulativePeriodSinceInception
7682000
rxii General And Administrative Employee Stock Based Compensation
GeneralAndAdministrativeEmployeeStockBasedCompensation
1565000
rxii Fair Value Of Common Stock Warrants Issued In Exchange For General And Administrative Expense
FairValueOfCommonStockWarrantsIssuedInExchangeForGeneralAndAdministrativeExpense
23000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2012-09-30
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2011-09-08
dei Entity Central Index Key
EntityCentralIndexKey
0001533040
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Trading Symbol
TradingSymbol
RXII
dei Entity Registrant Name
EntityRegistrantName
RXI PHARMACEUTICALS CORP
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
124000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
11897000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
118000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Reclassifications</i></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Certain prior period items have been reclassified to conform to the current year presentation.</font></p> </div>
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
63847938 shares
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9314000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
13000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y18D
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-147000
us-gaap Interest Paid
InterestPaid
29000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
130032178 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
14000
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
1711000
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
597000
us-gaap Share Based Compensation
ShareBasedCompensation
671000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.10
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5775000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11263000
us-gaap Revenue From Grants
RevenueFromGrants
57000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
671000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1000000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
208000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
26000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
208000
us-gaap Net Income Loss
NetIncomeLoss
-11168000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0094 pure
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
9500000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2006000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9673000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
2114000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8870 pure
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
8500000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-42000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
500000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6173000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9000
us-gaap Sales Revenue Net
SalesRevenueNet
57000
us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
2397000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
13000
rxii Preferred Stock Beneficial Conversion Feature
PreferredStockBeneficialConversionFeature
9500000
rxii Research And Development Employee Stock Based Compensation Expense
ResearchAndDevelopmentEmployeeStockBasedCompensationExpense
282000
rxii Research And Development Non Employee Stock Based Compensation Expense
ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense
107000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3912000
rxii Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
rxii Future Milestone Payments
FutureMilestonePayments
45000000
rxii Interest Income Expense
InterestIncomeExpense
29000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23065000
us-gaap Preferred Stock Redemption Discount
PreferredStockRedemptionDiscount
9500000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
2000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
764146712 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Uses of estimates in preparation of financial statements</i></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</font></p> </div>
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
35000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.07
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-232000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
25000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2752000
rxii Entity Incorporation Date Of Incorporation End Date
EntityIncorporationDateOfIncorporationEndDate
2011-09-23
rxii Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodIntrinsicValue
rxii Patent And Technology Rights Expenses
PatentAndTechnologyRightsExpenses
6173000
rxii Common Stock Warrants Issued For General And Administrative Expenses
CommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses
13000
rxii Combined Results Of Operation Of Cumulative Period Since Inception
CombinedResultsOfOperationOfCumulativePeriodSinceInception
25602000
rxii Cash Contributions From Parent Company Net
CashContributionsFromParentCompanyNet
-699000
rxii Adjustments To Additional Paid In Capital Expenses Paid By Parent Company
AdjustmentsToAdditionalPaidInCapitalExpensesPaidByParentCompany
699000
rxii Maximum Annual Net Sales Achieve In First Payment
MaximumAnnualNetSalesAchieveInFirstPayment
500000000
rxii Maximum Annual Net Sales Achieve In Second Payment
MaximumAnnualNetSalesAchieveInSecondPayment
1000000000
rxii Non Cash Equity Transactions
NonCashEquityTransactions
71726000
rxii Future Milestone Payments First Payment
FutureMilestonePaymentsFirstPayment
15000000
rxii Future Milestone Payments Second Payment
FutureMilestonePaymentsSecondPayment
30000000
rxii General And Administrative Employee Stock Based Compensation
GeneralAndAdministrativeEmployeeStockBasedCompensation
282000
rxii Forfeiture Rate For Options Granted To Directors
ForfeitureRateForOptionsGrantedToDirectors
0.00 pure
rxii Forfeiture Rate For Options Granted To Employees
ForfeitureRateForOptionsGrantedToEmployees
0.050 pure
rxii Percentage Of Fully Diluted Shares Issued Upon Completion Of Spin Off Transaction
PercentageOfFullyDilutedSharesIssuedUponCompletionOfSpinOffTransaction
0.05 pure
rxii Stock Issued During Period Shares Issued For Exchange Of Patent And Technology Rights
StockIssuedDuringPeriodSharesIssuedForExchangeOfPatentAndTechnologyRights
41849934 shares
rxii Distribution Ratio Description
DistributionRatioDescription
One share of RXi common stock for every one share of Galena common stock.
CY2012Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio
StockholdersEquityNoteStockSplitConversionRatio
1004397.41 Ratio
CY2012Q2 us-gaap Stock Issued During Period Shares Stock Splits
StockIssuedDuringPeriodSharesStockSplits
100439841 shares
CY2012Q2 rxii Number Of Share Distributed To Shareholders By Parent Company
NumberOfShareDistributedToShareholdersByParentCompany
66959894 shares
CY2011Q3 us-gaap Stock Issued During Period Value Issued For Noncash Considerations
StockIssuedDuringPeriodValueIssuedForNoncashConsiderations
1.00
CY2011Q3 us-gaap Stock Issued During Period Shares Issued For Cash
StockIssuedDuringPeriodSharesIssuedForCash
100 shares
CY2011Q3 rxii Issuance Price Of Initial Shares
IssuancePriceOfInitialShares
0.01
CY2011Q3 rxii Maintenance Costs To Be Paid Under Agreement
MaintenanceCostsToBePaidUnderAgreement
100000
CY2011Q3 rxii Percentage Of Royalty Required To Pay
PercentageOfRoyaltyRequiredToPay
0.01 pure
rxii Combined Results Of Operation Of Cumulative Period Since Inception
CombinedResultsOfOperationOfCumulativePeriodSinceInception
73466000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6440000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
11897000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
782000
us-gaap Stock Issued1
StockIssued1
978000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-865000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
55045000
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
277000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
669000
us-gaap Interest Paid
InterestPaid
37000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-38000
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
27177000
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
390000
us-gaap Share Based Compensation
ShareBasedCompensation
18637000
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
724000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6278000
us-gaap Operating Income Loss
OperatingIncomeLoss
-94211000
us-gaap Revenue From Grants
RevenueFromGrants
57000
us-gaap Net Income Loss
NetIncomeLoss
-87171000
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
9500000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
39223000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1000000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
37497000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
269000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-35000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
208000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
65154000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
2114000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
8500000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
128000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1000000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
53000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
754000
us-gaap Sales Revenue Net
SalesRevenueNet
57000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
13000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-99068000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
47000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
37532000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
50000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1213000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
155000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
24000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
35625000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-58011000
rxii Noncash Rent Expense
NoncashRentExpense
29000
rxii Interest Income Expense
InterestIncomeExpense
-600000
rxii Preferred Stock Beneficial Conversion Feature
PreferredStockBeneficialConversionFeature
9500000
rxii Research And Development Employee Stock Based Compensation Expense
ResearchAndDevelopmentEmployeeStockBasedCompensationExpense
3202000
rxii Research And Development Non Employee Stock Based Compensation Expense
ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense
6091000
rxii Reclassification Of Derivative Liability Upon Elimination Of Obligation
ReclassificationOfDerivativeLiabilityUponEliminationOfObligation
9249000
rxii Patent And Technology Rights Expenses
PatentAndTechnologyRightsExpenses
6173000
rxii Other Significant Noncash Transaction Equipment And Furnishings Exchanged For Parent Company Common Stock
OtherSignificantNoncashTransactionEquipmentAndFurnishingsExchangedForParentCompanyCommonStock
48000
rxii Other Significant Noncash Transaction Value Of Parent Company Restricted Stock Units And Common Stock Issued In Lieu Of Cash Bonuses
OtherSignificantNoncashTransactionValueOfParentCompanyRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses
207000
rxii Value Of Parent Company Restricted Stock Units Issued In Lieu Of Bonuses Included In Accrued Expenses
ValueOfParentCompanyRestrictedStockUnitsIssuedInLieuOfBonusesIncludedInAccruedExpenses
427000
rxii Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financing
ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancing
5604000
rxii Common Stock Warrants Issued For General And Administrative Expenses
CommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses
2398000
rxii Cash Contributions From Parent Company Net
CashContributionsFromParentCompanyNet
-55923000
rxii Allocation Of Management Expenses
AllocationOfManagementExpenses
551000
rxii Loss On Exchange Of Equity Instruments
LossOnExchangeOfEquityInstruments
900000
rxii General And Administrative Employee Stock Based Compensation
GeneralAndAdministrativeEmployeeStockBasedCompensation
9344000
rxii Fair Value Of Shares Mandatorily Redeemable For Cash Upon Exercise Of Warrants
FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants
785000
rxii Fair Value Of Derivatives Issued In Connection With Parent Company Common Stock Recorded As Cost Of Equity
FairValueOfDerivativesIssuedInConnectionWithParentCompanyCommonStockRecordedAsCostOfEquity
14051000
rxii Fair Value Of Derivatives Issued In Exchange For Services
FairValueOfDerivativesIssuedInExchangeForServices
2385000
rxii Fair Value Of Common Stock Warrants Issued In Exchange For General And Administrative Expense
FairValueOfCommonStockWarrantsIssuedInExchangeForGeneralAndAdministrativeExpense
304000
rxii Fair Value Of Parent Company Shares Mandatorily Redeemable For Cash Upon Exercise Of Warrants
FairValueOfParentCompanySharesMandatorilyRedeemableForCashUponExerciseOfWarrants
785000
rxii Fair Value Of Parent Company Stock Options Modified
FairValueOfParentCompanyStockOptionsModified
960000
rxii Fair Value Of Common Stock Issued In Exchange For Licensing Rights
FairValueOfCommonStockIssuedInExchangeForLicensingRights
3954000
CY2005 us-gaap Net Income Loss
NetIncomeLoss
-2209000
CY2005 rxii Net Transactions With Parent
NetTransactionsWithParent
2727000
CY2006 us-gaap Net Income Loss
NetIncomeLoss
-2405000
CY2006 rxii Net Transactions With Parent
NetTransactionsWithParent
2587000
CY2006 rxii Cash Contributions From Parent Company
CashContributionsFromParentCompany
2000
CY2007 us-gaap Net Income Loss
NetIncomeLoss
-10990000
CY2007 rxii Stock Based Compensation Expense
StockBasedCompensationExpense
1814000
CY2007 rxii Cash Contributions From Parent Company
CashContributionsFromParentCompany
15679000
CY2007 rxii Non Cash Equity Adjustments From Parent Company
NonCashEquityAdjustmentsFromParentCompany
4318000
CY2009 us-gaap Net Income Loss
NetIncomeLoss
-18387000
CY2009 rxii Stock Based Compensation Expense
StockBasedCompensationExpense
4202000
CY2009 rxii Cash Contributions From Parent Company
CashContributionsFromParentCompany
7714000
CY2009 rxii Non Cash Equity Adjustments From Parent Company
NonCashEquityAdjustmentsFromParentCompany
-1756000
CY2010 us-gaap Net Income Loss
NetIncomeLoss
-11993000
CY2010 rxii Stock Based Compensation Expense
StockBasedCompensationExpense
4368000
CY2010 rxii Cash Contributions To Parent Company
CashContributionsToParentCompany
11640000
CY2010 rxii Non Cash Equity Adjustments From Parent Company
NonCashEquityAdjustmentsFromParentCompany
-2326000
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
122000
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-2537000
CY2011 rxii Stock Based Compensation Expense
StockBasedCompensationExpense
1987000
CY2011 rxii Reclassification Of Derivative Liability Upon Elimination Of Obligation
ReclassificationOfDerivativeLiabilityUponEliminationOfObligation
9249000
CY2011 rxii Cash Contributions From Parent Company
CashContributionsFromParentCompany
1500000
CY2011 rxii Cash Contributions To Parent Company
CashContributionsToParentCompany
369000
CY2011 rxii Adjustments To Additional Paid In Capital Expenses Paid By Parent Company
AdjustmentsToAdditionalPaidInCapitalExpensesPaidByParentCompany
2058000
CY2011 rxii Net Income Loss Attributable To Predecessor Company
NetIncomeLossAttributableToPredecessorCompany
-7682000
CY2011 rxii Non Cash Equity Adjustments From Parent Company
NonCashEquityAdjustmentsFromParentCompany
-8083000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
13705000
CY2012 rxii Combined Results Of Operation Of Cumulative Period Since Inception
CombinedResultsOfOperationOfCumulativePeriodSinceInception
25602000
CY2004 us-gaap Net Income Loss
NetIncomeLoss
-3272000
CY2004 rxii Net Transactions With Parent
NetTransactionsWithParent
2393000
CY2008 us-gaap Net Income Loss
NetIncomeLoss
-14373000
CY2008 rxii Stock Based Compensation Expense
StockBasedCompensationExpense
3824000
CY2008 rxii Cash Contributions From Parent Company
CashContributionsFromParentCompany
7944000
CY2008 rxii Non Cash Equity Adjustments From Parent Company
NonCashEquityAdjustmentsFromParentCompany
750000
CY2011Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
123000
CY2011Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2011Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1126000
CY2011Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41970481 shares
CY2011Q3 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
730000
CY2011Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2167000
CY2011Q3 us-gaap Net Income Loss
NetIncomeLoss
-2043000
CY2011Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1041000
CY2011Q3 rxii Interest Income Expense
InterestIncomeExpense
-1000
CY2011Q3 rxii Research And Development Employee Stock Based Compensation Expense
ResearchAndDevelopmentEmployeeStockBasedCompensationExpense
79000
CY2011Q3 rxii Research And Development Non Employee Stock Based Compensation Expense
ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense
26000
CY2011Q3 rxii Common Stock Warrants Issued For General And Administrative Expenses
CommonStockWarrantsIssuedForGeneralAndAdministrativeExpenses
10000
CY2011Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2043000
CY2011Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1021000
CY2011Q3 rxii Combined Results Of Operation Of Cumulative Period Since Inception
CombinedResultsOfOperationOfCumulativePeriodSinceInception
1959000
CY2011Q3 rxii General And Administrative Employee Stock Based Compensation
GeneralAndAdministrativeEmployeeStockBasedCompensation
301000
CY2012Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
53000
CY2012Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
1277000
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1214000
CY2012Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
157155222 shares
CY2012Q3 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
387000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1696000
CY2012Q3 us-gaap Revenue From Grants
RevenueFromGrants
57000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-1644000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0157 pure
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
539000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.1520 pure
CY2012Q3 us-gaap Sales Revenue Net
SalesRevenueNet
57000
CY2012Q3 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
1277000
CY2012Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2921000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.14
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2012Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1069000
CY2012Q3 rxii Interest Income Expense
InterestIncomeExpense
1000
CY2012Q3 rxii Research And Development Employee Stock Based Compensation Expense
ResearchAndDevelopmentEmployeeStockBasedCompensationExpense
138000
CY2012Q3 rxii Research And Development Non Employee Stock Based Compensation Expense
ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense
7000
CY2012Q3 rxii General And Administrative Employee Stock Based Compensation
GeneralAndAdministrativeEmployeeStockBasedCompensation
152000
CY2011Q3 rxii Combined Results Of Operation Of Cumulative Period Since Inception
CombinedResultsOfOperationOfCumulativePeriodSinceInception
-84000

Files In Submission

Name View Source Status
0001193125-12-467372-index-headers.html Edgar Link pending
0001193125-12-467372-index.html Edgar Link pending
0001193125-12-467372.txt Edgar Link pending
0001193125-12-467372-xbrl.zip Edgar Link pending
d417515d10q.htm Edgar Link pending
d417515dex311.htm Edgar Link pending
d417515dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rxii-20120930.xml Edgar Link completed
rxii-20120930.xsd Edgar Link pending
rxii-20120930_cal.xml Edgar Link unprocessable
rxii-20120930_def.xml Edgar Link unprocessable
rxii-20120930_lab.xml Edgar Link unprocessable
rxii-20120930_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending